# **UKnight**

**INVESTOR FACT SHEET** August 2023

## **CORPORATE PROFILE**

Knight Therapeutics Inc. (TSX: GUD), founded in 2014 by Jonathan Ross Goodman (co-founder of Paladin Labs Inc.), is a pan-American (ex-USA) specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight is headquartered in Montreal, Quebec, Canada and has nearly 700 employees.

## **OUR FOOTPRINT**



#### MARKET FACTS (As at August 3, 2023)

As al August 3, 2023)

Symbol: TSX: GUD Share Price: \$4.75 Shares Outstanding: 106.8 M Market Capitalization: \$507.1 M

## MANAGEMENT TEAM

Samira Sakhia President and CEO

Amal Khouri Chief Business Officer Arvind Utchanah

Chief Financial Officer

Susan Emblem Global VP Human Resources

Monica Percario Global VP Scientific Affairs

Leopoldo Bosano VP, Manufacturing and Operations Henrique Dias

Global Director of Marketing

### **BOARD OF DIRECTORS**

Jonathan Ross Goodman (Executive Chairman) James Gale (Lead Director) Samira Sakhia Robert Lande Janice Murray Michael Tremblay Nicolás Sujoy

#### **INVESTOR CONTACT** Knight Therapeutics Inc.

Samira Sakhia, President and CEO Tel: 514.484.4483

Arvind Utchanah, CFO Tel: 598.2626.2344

E-mail: info@knighttx.com Website: www.knighttx.com


# FINANCIAL RESULTS

In '000s of CAD except per share amounts


	Q2 2023	Q3 2022	TTM Q2-23	TTM Q2-22
Revenues	89,905	72,281	326,438	271,240
Cash inflow (outflow) from operations	(1,486)	11,329	18,306	39,402
Adjusted EBITDA <sup>2</sup>	14,269	9,009	55,336	54,232
Per share	0.13	0.08	0.52	0.47
	06-30-2023	12-31-2022		
Net cash <sup>1</sup> , marketable securities and financial	000 0 40	070 405		
assets	230,043	279,165		
Per share	2.15	2.48		
Net asset value	807,199	825,857		
Per share	7.53	7.33		

<sup>1</sup> Net of bank loans

<sup>2</sup> Adjusted EBITDA is operating income (loss) adjusted to exclude amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases.



## FINANCIAL HIGHLIGHTS



Note: Revenues exclude impact of hyperinflation/ IAS29 Adjusted EBITDA is a non-GAAP measure and defined as operating income or loss adjusted to exclude amortization and depreciation, impairment of non-current assets, purchase price allocation accounting adjustments, the impact of IAS 29 (accounting under hyperinflation), acquisition costs and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

# **CORPORATE RESPONSIBILITY**

#### Access to healthcare

Knight focuses on acquiring, in-licensing and commercializing of innovative products, as well as developing, manufacturing and marketing of specialty pharmaceutical products in Latin America, Canada and select international markets.

Knight continues to work diligently to ensure patients have access to Knight's medications in its markets and to develop branded generic products for Latin America to ensure that Knight provides cost effective treatments.

# **INVESTMENT HIGHLIGHTS**

- Strong regional infrastructure with a unique footprint in Canada and across 10 countries in Latin America
- · Experienced and dynamic management team
- Proven ability to develop a rich pipeline of new products and to secure mutually beneficial transactions
  Proven track record of profitable growth
- Financial strength to execute our strategy

# ANALYST COVERAGE

Bloom Burton & Co. David Martin dmartin@bloomburton.com

#### **Canaccord Genuity**

Tania Armstrong-Whitworth tarmstrongwhitworth@cgf.com

National Bank Financial Endri Leno endri.leno@nbc.ca

Stifel GMP Justin Keywood jkeywood@stifel.com

Research Capital Andre Uddin auddin@researchcapital.com Paradigm Capital Inc Scott McAuley smcauley@paradigmcap.com

RBC Capital Markets Douglas Miehm douglas.miehm@research.rbccm.com